# US 7,745,151 B2 · Methods of determining binding between Nogo receptor and p75 neurotrophin receptor > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,745,151 B2 - Document ID: US7745151B2 - Status: Granted - Kind: B2 - Application number: 10/211,157 - Filed: 2002-08-02 - Published: 2004-02-12 - Granted: 2010-06-29 - Earliest claimed: 2002-08-02 - Assignees: Children's Medical Center Corporation - Inventors: Zhigang He; Kevin C. Wang; Jieun A. Kim - Web page: https://patentgrep.com/patent/US7745151B2 ## CPC - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor} - C07K 16/2863: {against receptors for growth factors, growth regulators} - G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2317/55: Fab or Fab' - C07K 2319/00: Fusion polypeptide - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Inhibitors of Nogo Receptor (NgR)-p75 binding are used to reduce NgR-p75 binding mediated axon growth inhibition. Mixtures of NgR and p75 are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to p75 and promoting axon regeneration. ## Claims ### Claim 1 A method for assaying Nogo receptor (NgR)-neurotrophin receptor p75NTR (p75) binding, the method comprising the steps of: providing a mixture comprising a p75-binding NgR domain and an NgR-binding p75 domain; and directly measuring binding of the NgR domain to the p75 domain as an indication of the assayed NgR-p75 binding. ### Claim 2 (depends on 1) A method according to claim 1, wherein binding of the NgR domain to the p75 domain is measured in the presence of an inhibitor of NgR-p75 binding and compared to a control amount of binding in the absence of the inhibitor, and wherein binding in the presence of the inhibitor is lower than the control binding. ### Claim 3 (depends on 2) A method according to claim 2, wherein the inhibitor is selected from the group consisting of: an NgR peptide, a p75 peptide, an NgR peptide-specific antibody fragment and a p75 peptide-specific antibody fragment. ### Claim 4 (depends on 1) A method according to claim 1, wherein one of the NgR domain and the p75 domain is soluble. ### Claim 5 (depends on 1) A method according to claim 1, wherein one of the NgR domain and the p75 domain is expressed on the surface of a cell. ### Claim 6 (depends on 1) A method according to claim 1, wherein the mixture is cell-free. ### Claim 7 (depends on 1) A method according to claim 1, wherein the mixture comprises an NgR comprising the NgR domain, and a p75 extracellular domain comprising the p75-domain. ### Claim 8 (depends on 1) A method according to claim 1, wherein one of the NgR domain and p75 domain is soluble and the other is expressed on the surface of a cell. ### Claim 9 (depends on 1) A method according to claim 1 wherein the measuring step is a co-immunoprecipitation assay, a solid phase ELISA-type assay, or a fluorescent polarization assay. ### Claim 10 A method for characterizing an agent as modulating Nogo receptor (NgR)-neurotrophin receptor p75NTR (p75) binding, the method comprising the steps of: A) incubating a mixture comprising a p75-binding NgR domain and an NgR-binding p75 domain under conditions that allow for binding between the two domains and directly measuring the degree of binding between the two domains, and B) incubating a mixture comprising a p75-binding NgR domain, an NgR-binding p75 domain, and an agent under the same conditions as in A), and directly measuring the degree of binding between the two domains; wherein a difference between the binding measured in A) and the binding measured in B) indicates that the agent modulates NgR-p75 binding. ### Claim 11 (depends on 10) A method according to claim 10, wherein one of the NgR domain and the p75 domain is soluble. ### Claim 12 (depends on 10) A method according to claim 10, wherein one of the NgR domain and the p75 domain is recombinantly expressed on the surface of a cell. ### Claim 13 (depends on 10) A method according to claim 10, wherein the mixture is cell-free. ### Claim 14 (depends on 10) A method according to claim 10, wherein the mixture comprises an NgR comprising the NgR domain, and a p75 extracellular domain comprising the p75-domain. ### Claim 15 (depends on 10) A method according to claim 10, wherein one of the NgR domain and p75 domain is soluble and the other is expressed on the surface of a cell. ### Claim 16 (depends on 10) A method according to claim 10 wherein the detecting step is a co-immunoprecipitation assay, a solid phase ELISA-type assay, or a fluorescent polarization assay. ### Claim 17 A method for assaying Nogo receptor (NgR)-neurotrophin receptor p75NTR (p75) binding, the method comprising the steps of: recombinantly expressing a p75-binding NgR domain and an NgR-binding p75 domain; and measuring binding of the NgR domain to the p75 domain. ### Claim 18 (depends on 17) A method according to claim 17, wherein binding of the NgR domain to the p75 domain is measured in the presence of an inhibitor of NgR-p75 binding and compared to a control amount of binding in the absence of the inhibitor, and wherein binding in the presence of the inhibitor is lower than the control binding. ### Claim 19 (depends on 17) A method according to claim 17, wherein one of the NgR domain and the p75 domain is soluble. ### Claim 20 (depends on 17) A method according to claim 17, wherein one of the NgR domain and the p75 domain is expressed on the surface of a cell. ### Claim 21 (depends on 17) A method according to claim 17, wherein the mixture is cell-free.